Tag: infectious disease clinical trials market forecast

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Infectious Disease Clinical Trials Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The infectious disease clinical trials market size has grown strongly in recent years. It will grow from $15.1 billion in 2025 to $16.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to expansion of global infectious disease burden, increased funding for vaccine development, growth in multinational clinical trial networks, adoption of digital trial management systems, rising public health research initiatives.

The infectious disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing investments in pandemic preparedness, rising use of ai-assisted patient recruitment, expansion of global trial decentralization, growing focus on accelerated regulatory approvals, increasing integration of digital biomarkers. Major trends in the forecast period include increasing adoption of data-driven trial design, rising use of decentralized clinical trial models, growing integration of real-world evidence, expansion of adaptive trial methodologies, enhanced focus on rapid pathogen response.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp

Infectious Disease Clinical Trials Market Growth Factors Supporting Long-Term Expansion

The rising healthcare infrastructure is expected to propel the growth of the infectious disease clinical trials market going forward. Healthcare infrastructure refers to the physical facilities, medical equipment, technologies, and trained workforce that support the delivery of healthcare services and enable effective disease prevention, diagnosis, and treatment. Healthcare infrastructure development is rising due to the increasing demand for advanced medical services, the growing burden of emerging and complex diseases, and the need for well-equipped facilities and skilled healthcare professionals to provide timely diagnosis, treatment, and preventive care. Healthcare infrastructure directly supports clinical trial capacity by providing advanced medical facilities, specialized equipment, and enhanced research capabilities essential for conducting comprehensive infectious disease studies. For instance, in January 2025, according to the American Hospital Association, a US-based non-profit organization, total number of hospitals in the United States is projected to reach 6,093 by 2025, reflecting a modest growth in healthcare facilities nationwide. Therefore, the rising healthcare infrastructure is driving the growth of the infectious disease clinical trials market.

Infectious Disease Clinical Trials Market Segment Outlook: Which Categories Are Expanding The Fastest?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

Infectious Disease Clinical Trials Market Industry Trends Shaping Future Revenue Growth

Major companies operating in the infectious disease clinical trials market are focusing on developing advanced research initiatives, such as phase 3 trials of antibiotic candidates, to help identify rare side effects and confirm optimal dosing. A phase 3 trial of antibiotic candidates is a late-stage study that tests the drug in a large group of patients to evaluate its safety, effectiveness, and how it compares to existing treatments before it can be approved for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, launched a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic specifically designed to combat CRAB, a critical cause of severe hospital infections worldwide. Zosurabalpin’s unique feature lies in its novel mechanism of action, which blocks the transport of lipopolysaccharide essential for building the bacterial outer membrane, with no resistance reported so far. The global trial will involve approximately 400 patients to evaluate its safety and effectiveness compared to standard treatments. Early research has shown powerful activity against multidrug-resistant bacteria, excellent tolerability, and promising pharmacokinetic properties. This positions Zosurabalpin as a potentially groundbreaking solution in addressing the urgent challenge of antibiotic resistance.

Infectious Disease Clinical Trials Market Key Companies And Competitive Benchmarking

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Access The Complete Infectious Disease Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Infectious Disease Clinical Trials Market Largest Region By Revenue And Market Share

North Americawas the largest region in the infectious disease clinical trials market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Infectious Disease Clinical Trials Market By 2030 Based On Its 2026 Value?

The infectious disease clinical trials market has experienced robust growth in recent years. It is anticipated to increase from $15.1 billion in 2025 to $16.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. The historical expansion can be linked to the escalating global infectious disease burden, enhanced funding for vaccine development, the proliferation of multinational clinical trial networks, the implementation of digital trial management systems, and surging public health research initiatives.

The infectious disease clinical trials market is anticipated to experience robust growth in the upcoming years, projected to reach $21.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is attributed to escalating investments in pandemic preparedness, the increasing application of AI-assisted patient recruitment, the broader implementation of global trial decentralization, a heightened focus on accelerated regulatory approvals, and the growing integration of digital biomarkers. Significant trends foreseen for the forecast period include the rising adoption of data-driven trial design, increased utilization of decentralized clinical trial models, the deepening integration of real-world evidence, the expansion of adaptive trial methodologies, and an enhanced focus on rapid pathogen response.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp

Which Major Factors Are Contributing To The Development Of The Infectious Disease Clinical Trials Market?

The expansion of healthcare infrastructure is anticipated to fuel the progress of the infectious disease clinical trials market moving ahead. This infrastructure encompasses physical facilities, medical technology, equipment, and a skilled workforce crucial for delivering healthcare services and facilitating disease prevention, diagnosis, and treatment. The development of healthcare infrastructure is increasing due to a higher demand for sophisticated medical services, the escalating prevalence of new and intricate diseases, and the necessity for adequately equipped facilities and proficient healthcare personnel to ensure prompt diagnosis, treatment, and preventive measures. Such infrastructure directly boosts clinical trial capabilities by offering state-of-the-art medical facilities, specialized apparatus, and improved research capacities, all vital for executing thorough infectious disease investigations. As an illustration, the American Hospital Association, a US-based non-profit organization, forecasts that by January 2025, the total number of hospitals in the United States will reach 6,093, indicating a steady increase in healthcare facilities across the nation. Consequently, the growing healthcare infrastructure is a significant impetus for the expansion of the infectious disease clinical trials market.

Which Segment Divisions Form The Structure Of The Infectious Disease Clinical Trials Market?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

What Trends Are Affecting The Growth Of The Infectious Disease Clinical Trials Market?

Leading organizations within the infectious disease clinical trials market are concentrating on developing advanced research initiatives, such as phase 3 trials for antibiotic candidates, to help uncover rare side effects and confirm optimal dosages. A phase 3 trial of antibiotic candidates is a late-stage investigation that tests the medication in a large patient population to assess its safety, efficacy, and comparison to existing treatments before gaining approval for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, initiated a Phase 3 clinical trial for zosurabalpin, an innovative tethered macrocyclic peptide antibiotic specifically engineered to combat CRAB, a significant cause of severe hospital infections globally. Zosurabalpin’s unique characteristic lies in its novel mechanism of action, which obstructs the transport of lipopolysaccharide essential for constructing the bacterial outer membrane, with no resistance observed so far. This global trial will encompass approximately 400 patients to evaluate its safety and effectiveness when compared to standard treatments. Preliminary research has indicated potent activity against multidrug-resistant bacteria, excellent tolerability, and promising pharmacokinetic properties. This places Zosurabalpin as a potentially groundbreaking remedy in tackling the urgent challenge of antibiotic resistance.

Who Are The Major Companies Operating In The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Access The Complete Infectious Disease Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Area Represents The Largest Portion Of The Infectious Disease Clinical Trials Market?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Infectious Disease Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=29097&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company

Hospital Acquired Infection Control Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Infection Prevention Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

Infection Control Supplies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Infectious Disease Clinical Trials Market Projected To Reach By 2030?

The infectious disease clinical trials market size has shown robust expansion in recent years. This market is set to increase from $15.1 billion in 2025 to $16.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical growth of this market can be attributed to the growing global burden of infectious diseases, increased financial support for vaccine development, the development of multinational clinical trial networks, the adoption of digital systems for trial management, and an increase in public health research efforts.

The infectious disease clinical trials market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $21.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is fueled by several factors, including greater investments in pandemic preparedness, the increasing adoption of AI-assisted patient recruitment, the broadening of global trial decentralization, a heightened emphasis on accelerated regulatory approvals, and the expanding incorporation of digital biomarkers. Significant developments expected in this period encompass the wider embrace of data-driven trial design, a surge in the application of decentralized clinical trial models, the deepening integration of real-world evidence, the proliferation of adaptive trial methodologies, and an increased commitment to rapid pathogen response.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Strong Drivers Are Impacting The Infectious Disease Clinical Trials Market Growth?

The expansion of healthcare infrastructure is anticipated to fuel the future growth of the infectious disease clinical trials market. This infrastructure encompasses physical sites, medical apparatus, technological advancements, and a skilled workforce, all vital for providing healthcare services and facilitating effective disease prevention, diagnosis, and treatment. The surge in healthcare infrastructure development is attributed to a heightened demand for sophisticated medical services, the increasing prevalence of novel and intricate diseases, and the necessity for adequately equipped facilities staffed by proficient healthcare personnel to ensure prompt diagnosis, therapy, and preventative measures. It directly bolsters clinical trial capacity through the provision of cutting-edge medical facilities, specialized instruments, and improved research capabilities, which are crucial for executing thorough infectious disease investigations. For instance, in January 2025, the American Hospital Association, a US-based non-profit organization, projected that the total number of hospitals in the United States will reach 6,093 by 2025, indicating a steady increase in healthcare facilities across the nation. Consequently, the expansion of healthcare infrastructure is a significant driver for the growth of the infectious disease clinical trials market.

What Are The Different Segment Types In The Infectious Disease Clinical Trials Market Segment Breakdown?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

Which Trends Are Contributing To Changes In The Infectious Disease Clinical Trials Market?

Leading companies within the infectious disease clinical trials market are concentrating on advancing research efforts, such as Phase 3 trials for antibiotic candidates, to pinpoint rare side effects and establish optimal dosages. A Phase 3 trial for antibiotic candidates represents a late-stage investigation, testing the drug across a large patient population to assess its safety, effectiveness, and comparison to existing treatments before potential approval for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, initiated a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic specifically engineered to combat CRAB, a critical global source of severe hospital infections. Zosurabalpin’s unique characteristic lies in its innovative mechanism of action, which prevents the transport of lipopolysaccharide essential for constructing the bacterial outer membrane, with no resistance yet reported. The global trial plans to enroll approximately 400 patients to evaluate its safety and effectiveness in comparison to standard treatments. Preliminary research has indicated potent activity against multidrug-resistant bacteria, excellent tolerability, and encouraging pharmacokinetic properties. This positions Zosurabalpin as a potentially transformative solution in addressing the critical challenge of antibiotic resistance.

Who Are The Well-Known Companies In The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Get The Full Infectious Disease Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Region Accounts For The Largest Portion Of The Infectious Disease Clinical Trials Market?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Infectious Disease Clinical Trials Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company

Clinical Trial Management Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-management-systems-global-market-report

Virtual Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report

Clinical Trial Supplies Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Infectious Disease Clinical Trials Market Projected To Become By 2030 Based On Its 2026 Valuation?

Significant growth has been observed in the infectious disease clinical trials market size recently. Projections indicate it will expand from $15.1 billion in 2025 to $16.13 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth is linked to factors such as an increasing global infectious disease burden, enhanced financial support for vaccine creation, the development of multinational clinical trial networks, the implementation of digital trial management systems, and a rise in public health research efforts.

The infectious disease clinical trials market size is projected to experience robust expansion over the coming years. This market is forecast to reach $21.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. The anticipated growth during this period is attributed to factors such as heightened investments in pandemic preparedness, the increasing adoption of AI-assisted patient recruitment, wider implementation of global trial decentralization, an intensifying emphasis on accelerated regulatory approvals, and greater integration of digital biomarkers. Key developments expected in the forecast period include a greater embrace of data-driven trial design, the increased utilization of decentralized clinical trial models, deeper integration of real-world evidence, the broadening application of adaptive trial methodologies, and a stronger focus on rapid pathogen response.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Infectious Disease Clinical Trials Market?

The increasing healthcare infrastructure is anticipated to drive the expansion of the infectious disease clinical trials market in the future. Healthcare infrastructure encompasses physical facilities, medical equipment, technologies, and skilled personnel crucial for delivering healthcare services and facilitating effective disease prevention, diagnosis, and treatment. The development of healthcare infrastructure is accelerating due to a higher demand for advanced medical services, the increasing prevalence of new and complex diseases, and the requirement for well-equipped facilities and proficient healthcare professionals to ensure prompt diagnosis, treatment, and preventive care. This infrastructure directly bolsters clinical trial capacity through the provision of cutting-edge medical facilities, specialized equipment, and improved research capabilities vital for executing thorough infectious disease studies. As an illustration, in January 2025, the American Hospital Association, a US-based non-profit organization, forecast that the total number of hospitals in the United States would reach 6,093 by 2025, indicating a slight expansion in healthcare facilities across the nation. Consequently, the expansion of healthcare infrastructure serves as a key driver for the growth of the infectious disease clinical trials market.

What Segment Groups Are Identified Within The Infectious Disease Clinical Trials Market?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

What Key Trends Are Influencing The Development Of The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are concentrating on developing sophisticated research initiatives, such as phase 3 trials for antibiotic candidates, to assist in discovering rare side effects and establishing optimal dosing. A phase 3 trial for antibiotic candidates is a late-stage investigation that tests the drug in a substantial patient group to evaluate its safety, effectiveness, and comparison to existing treatments before it can be approved for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, commenced a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic specifically engineered to combat CRAB, a critical contributor to severe hospital infections worldwide. Zosurabalpin’s distinctive characteristic lies in its novel mechanism of action, which impedes the transport of lipopolysaccharide essential for building the bacterial outer membrane, with no resistance observed to date. This global trial will encompass approximately 400 patients to assess its safety and effectiveness when contrasted with standard treatments. Preliminary research has demonstrated powerful activity against multidrug-resistant bacteria, excellent tolerability, and encouraging pharmacokinetic properties. This positions Zosurabalpin as a potentially revolutionary solution in tackling the urgent challenge of antibiotic resistance.

Which Companies Hold Significant Positions In The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Read the full infectious disease clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Regions Are Projected To Dominate The Infectious Disease Clinical Trials Market In The Coming Years?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Infectious Disease Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=29097&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company

Hospital Acquired Infection Control Global Market Report

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Infection Prevention Global Market Report

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

Infection Control Supplies Global Market Report

https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model